Compare VRAX & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRAX | GXAI |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United Kingdom | United States |
| Employees | 26 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 9.1M |
| IPO Year | 2021 | 2022 |
| Metric | VRAX | GXAI |
|---|---|---|
| Price | $2.86 | $0.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 199.1K | ★ 2.2M |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.35 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,933,030.00 |
| Revenue This Year | $217,274.83 | $271.23 |
| Revenue Next Year | N/A | $36.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 47901.74 |
| 52 Week Low | $0.10 | $0.73 |
| 52 Week High | $13.19 | $2.96 |
| Indicator | VRAX | GXAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 44.95 |
| Support Level | $0.19 | $0.73 |
| Resistance Level | $3.10 | $1.32 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 54.67 | 18.47 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.